Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Year-end report 2018 - Pricer AB (publ)

Record high growth and operating profit- The Board proposes a dividend of SEK 0.60 per share Fourth quarter 2018 · Net sales of SEK 386.5 M (253.0), an increase of 53 percent compared to the same period of last year · Operating profit of SEK 29.0 M (16.9), corresponding to an operating margin of 7.5 percent (6.7) · Order intake of SEK 274 M (231), an increase of 18 percent compared to the same period of last year · The order backlog increased to SEK 224 M (133), most of which is expected to be invoiced in the first half of 2019 · Profit for the period amounted to SEK

The plans 2019-2021 within UPM share incentive programmes

UPM-Kymmene Corporation      Other information disclosed according to the rules of the Exchange    14 February 2019 at 09:30 EET The plans 2019-2021 within UPM share incentive programmes UPM's Board of Directors has approved the commencement of new plans for the period 2019-2021 within the company's two long-term share incentive programmes: the Performance Share Plan and the Deferred Bonus Plan. The long-term share incentive programmes consist of annually commencing new plans subject to the approval of the Board of Directors of UPM in each case. The earning criterion for the

Decision to direct share issue to the European High Growth Opportunities Securitization Fund

The Board of Directors of QuickCool AB (publ) ("QuickCool"), supported by the authorization from the annual general meeting on May 3, 2018, decided a directed share issue, with exemption from the shareholders " preferential rights. The new share issue has been addressed to the European High Growth opportunities Securitization Fund.The purpose of the directed share issue has been to fulfil one of the terms of the financing agreement that Quickcool entered with the European High Growth Opportunities Securitization Fund. Information about the financing agreement was provided through a press

Notice of Ahlstrom-Munksjö’s Annual General Meeting

AHLSTROM-MUNKSJÖ OYJ STOCK EXCHANGE RELEASE FEBRUARY 14, 2019 at 09:15Notice is given to the shareholders of Ahlstrom-Munksjö Oyj to the Annual General Meeting to be held on Wednesday, March 27, 2019 at 1:00 p.m. (EET) at the Finlandia Hall, Helsinki-hall, Mannerheimintie 13 e, Helsinki, Finland (entrance M3 from Mannerheimintie and K3 from the Karamzininranta -street). The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 12:00 noon (EET). Registration for the meeting is requested to be made no later than 12:45 p.m. (EET).A.

Aspire Global’s Year-End Report 2018 – Concluding an Amazing Year

FOURTH QUARTER (OCT-DEC 2018) • Revenues increased by 71.6% to €32.9 million (19.2)• B2B Revenues increased by 87.3% to €19.3 million (10.3)• EBITDA increased by 71.4% to €6.6 million (3.8)• EBITDA margin amounted to 20.0% (20.0%)• EBIT increased to €6.0 million (3.5)• Earnings after tax from continued operations increased to €4.6 million (1.3)• Earnings per share after tax from continued operations increased to €0.10 (0.03)• Cash flow from operating activities increased by 103.9% to €5.3 million (2.6)• First time depositors (FTDs) increased by 82.1% to 123.7 thousand (67.

Terveystalo Plc: Notice of the Annual General Meeting

Terveystalo Plc Stock Exchange Release 14 February 2019 at 9:05 EET Notice is given to the shareholders of Terveystalo Plc of the Annual General Meeting to be held on Thursday, 4 April 2019 at 3:00 p.m. at Marina Congress Center, Katajanokanlaituri 6, Helsinki, Finland. The reception of attendees, who have registered for the meeting, will commence at 2:00 p.m. A. Matters on the agenda of the Annual General Meeting The following matters will be considered at the Annual General Meeting: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to

Year-end Report 1 January to 31 December 2018

Summary of the year-end reportFinancial year (1 January to 31 December 2018) · Operating revenue KSEK 1 (0) · Income after financial items KSEK -15 434 (-8 824) · Earnings per share -0,41 (-0,50) · Cash and cash equivalents as of 31 December 2018 KSEK 38 716 (33 357) · Equity ratio as of 31 December 2018 93,2 (90,4) % Fourth Quarter (1 October to 31 December 2018) · Operating revenue KSEK 1 (0) · Income after financial items KSEK -4 534 (-3 231) · Earnings per share -0,12 (-0,18) Significant events during the fourth quarter of 2018 · The company

CEO Robin Lindahl to leave Normet and join Taaleri

Robin Lindahl, President and CEO of Normet Group has decided to leave Normet.  He will join Taaleri plc as their new CEO latest 1.8.2019. Taaleri is listed on the Helsinki Stock Exchange and its business comprises of wealth management, financial services and renewable energy business.The search for a new President and CEO has already started and Mr. Lindahl will be actively supporting in the transfer of his duties forward over the coming months. “It has been a real pleasure leading Normet as CEO during the last 3 years. I will mostly miss the great team and the skilled colleagues at

Humana reports fourth quarter and full year results 2018

High organic growth and a Nordic care group in the making Fourth quarter, October-December 2018:  ·  Operating revenue was SEK 1,700 M (1,616), an increase of 5%. ·  Operating profit was SEK 82 M (SEK 66 M), an increase of 24 % or SEK 16 M. Excluding acquisition related costs, operating profit increased by 42% to SEK 95 M (67) for the period. ·  Net profit after tax for the period was SEK 51 M (34).   ·  Earnings per share for the period before and after dilution were SEK 0.97 (0.63).   ·  Operating cash flow was SEK 136 M (197).   Full year, January-December 2018

Sören Mellstig proposed as new Chairman of the Board of Humana

Ahead of the Annual General Meeting 2019 the Nomination Committee of Humana AB has decided to propose Sören Mellstig as the new Chairman of the Board.The Chairman of the Board, Per Båtelson, has after eleven years as a board member, including five years as its Chairman, declared that he is not available for re-election. The Nomination Committee has therefore decided to propose to the Annual General Meeting the election of Sören Mellstig as the new Chairman of the Board. Sören Mellstig is Chairman of Cellavision, Ellevio and Rkliniken, and Industrial Partner and co-founder of Impilo, one

AstraZeneca Full-Year and Q4 2018 Results

AstraZeneca PLC  14 February 2019 07:00 GMT     Full-year and Q4 2018 results  New launches and commercial execution deliver full-year sales growth and a very strong final quarter.  2019 anticipated to be a year of higher year-on-year sales growth combined with operating leverage.     The final quarter of the year saw a very strong performance, including Product Sales growth of 5% (8% at CER1) to $5,768m. In the year, Product Sales increased by 4% to $21,049m, reflecting the performance of new medicines2 (+81%) and the sustained strength of Emerging Markets (+12%, +13%

Attendo’s year-end report 2018 - Strong growth in own operations affects margins

Attendo continues to show strong growth in own operations, with a record number of new nursing home openings in the full year 2018. The combination of a high pace of openings and costs related to closing down other operations puts pressure on profitability. The possibilities to increase margins from current level is deemed limited during the current year and 2020.CEO and President Martin Tivéus comments on the report: “Continued growth in own operations Attendo demonstrated high growth in the fourth quarter and for the full year of 2018, a result of a record-high number of new homes

Proposal by the Nomination Committee regarding the Board of Directors of Cloetta AB

Cloetta’s Nomination Committee has informed the company of its proposal regarding new Board of Directors.The Nomination Committee proposes re-election of the current directors Lilian Fossum Biner, Mikael Aru, Lottie Knutson, Alan McLean Raleigh, Camilla Svenfelt and Mikael Svenfelt. Mikael Norman has declined re-election. Lilian Fossum Biner is proposed to be re-elected as the Chairman of the Board of Directors. Furthermore, the Nomination Committee proposes Patrick Bergander as new director. Patrick Bergander is since 2014 CEO of RSA Scandinavia (Codan/Trygg-Hansa) and has also been

Alligator Bioscience AB Year-end Report 2018

The bispecific drug candidate ATOR-1015 in clinical developmentSignificant events October-December• The Swedish MPA (Medical Products Agency) approved start of Phase I clinical trial of ATOR-1015.• New preclinical data for ATOR-1017 and ALG.APV-527 presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC).• The company expanded its pipeline and initiated preclinical development of the ATOR-1144 drug candidate.• Research funding granted from Vinnova.• Alligator Bioscience recorded a revenue of approximately USD 3 million related to a collaboration with

Summons to the Annual General Meeting of shareholders in Castellum AB (publ)

The shareholders of Castellum AB (publ), Reg. No. 556475-5550, are hereby summoned to the Annual General Meeting to be held on Thursday, March 21, 2019 at 5 pm in RunAn, Chalmers Kårhus, Chalmersplatsen 1, Gothenburg. The entrance opens at 4 pm.Notification etcShareholders wishing to attend the Annual General Meeting must be registered as share­holders in the share register kept by Euroclear Sweden AB by Friday, March 15, 2019 and must also have notified their attendance to the company no later than Friday, March 15, 2019 (pre­ferably before 4 pm).   Notification of attendance at the

European High Growth Opportunities Securitization Fund requests conversion of convertible bonds

European High Growth Opportunities Securitization Fund has by notice to the board of directors of QuickCool AB (Publ) ("QuickCool") called upon its right to conversion of convertible bonds previously issued in accordance with the financing solution announced by QuickCool through a press release on 21 June 2018.QuickCool has received notification from European High Growth Opportunities Securitization Fund regarding conversion of convertible bonds into 500 000 shares in QuickCool, corresponding to SEK 300 000 of the convertible loan. The conversion price per share is SEK 0,60. Upon

Eltel Group: Full-year report January–December 2018

October–December 2018 ·Net sales EUR 330.9 million (374.2). Total growth -11.6% and organic growth* in Power and Communication -5.1% ·Operative EBITA** EUR 2.9 million (2.2) and operative EBITA margin 0.9% (0.6) ·Operating result (EBIT) EUR -0.2 million (1.2) and EBIT margin -0.1% (0.3) ·Net result EUR -3.3 million (-7.7) ·Earnings per share EUR -0.02 (-0.05), basic and diluted ·Cash flow from operating activities EUR 70.0 million (42.3) January–December 2018 · Net sales EUR 1,188.9 million (1,329.9). Total growth -10.6% and organic growth*

Wihlborgs signs agreement with voestalpine Böhler weldCare AB to build new production facility in Malmö

Wihlborgs has signed a 15-year lease with voestalpine Böhler weldCare AB for 4,300 m². The lease will be used for a production facility of voestalpine Böhler weldCare AB that Wihlborgs will build at the Stenåldern 7 property in Fosie, Malmö.voestalpine Böhler weldCare AB is part of the voestalpine Böhler Welding Group, a leading manufacturer and worldwide supplier of filler metals for industrial welding and brazing applications. The lease from Wihlborgs is dedicated to a new state-of-the-art facility for the production of premium finishing chemicals of voestalpine Böhler weldCare AB.

InCoax appoints Håkan Rusk CSMO

Håkan Rusk has been appointed Chief Sales and Marketing Officer at InCoax and will play a critical role in the growth journey of the company.Håkan Rusk who joined InCoax as Chief Marketing Officer in September 2018, with approximately 24 years’ working experience in IT, telecommunications and application markets, has been appointed Chief Sales and Marketing Officer with immediate effect. Håkan Rusk will report to Peter Carlsson, CEO. Håkan Rusk has previously been the Director of Sales Management at Fingerprint Card AB 2013-2018, where he lead the work to scale the sales operations

BIMobject: Year-End Report and Interim Report  October – December 2018

The complete report is available on the Company’s website info.bimobject.com. Fourth quarter 2018 ·  Billing increased by 7 percent to SEK 59 (55) million. ·  The Group’s net sales increased by 2 percent to SEK 39 (38) million. The distribution between projects and web services (subscriptions) was 42/58 (44/56) percent. ·  The Group’s operating profit/loss amounted to SEK -34 (-4) million. ·  Basic earnings per share amounted to SEK -0.26 (-0.10). ·  Cash flow from operating activities was SEK -22 (-19) million. ·  The accumulated number of users increased to

IRRAS AB (PUBL) YEAR-END REPORT JANUARY–DECEMBER 2018

IRRAflow® launch initiated in the USFourth quarter, October–December 2018 · Net revenue totaled SEK 0.0 million (0.7). · Operating loss (EBIT) amounted to SEK -50.1 million (-23.7). · Loss after tax totaled SEK -50.1 million (-23.2). · Earnings per share before and after dilution amounted to SEK -2.09 (-1.09). Period January–December 2018 · Net revenue totaled SEK 6.0 million (12.0). · Operating loss (EBIT) amounted to SEK -143.3 million (-61.5). · Loss after tax totaled SEK -138.8 million (-60.9). · Earnings per share before and after dilution amounted to SEK

Camurus to present at the Cowen and Company Annual Healthcare Conference 2019

Lund, Sweden — 14 February 2019 — Camurus (NASDAQ STO: CAMX) today announces that Fredrik Tiberg, President and CEO, will provide an overview and update on the company's business at the Cowen and Company 39th Annual Healthcare Conference in Boston, Massachusetts. The presentation will take place on Monday 11 March 2019 at 4:10 pm Eastern Standard Time and can be accessed via a live webcast at Camurus website www.camurus.com. An archived version of the webcast will be available for 30 days after the event. About CamurusCamurus is a Swedish science-led biopharmaceutical company committed

Full Year Report January – December 2018

BioArctic’s partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer’s disease. AbbVie in-licensed the Parkinson portfolioOctober – December 2018 · Net revenues for the period amounted to SEK 515.3 million (51.0) · Operating profit amounted to SEK 430.3 million (14.7) · Profit for the period amounted to SEK 335.2 million (11.8) · Earnings per share were SEK 3.81 (0.16) · Cash flow from operating activities amounted to SEK -89.3 million (-45.7) January – December 2018 · Net revenues for the period amounted to SEK 714.0 million (140.7) ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top